- Home
- CMA vs BBIO Comparison
CMA vs BBIO Comparison
Compare CMA & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMA
- BBIO
- Stock Information
- Founded
- CMA 1849
- BBIO 2015
- Country
- CMA United States
- BBIO United States
- Employees
- CMA N/A
- BBIO N/A
- Industry
- CMA Major Banks
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- CMA Finance
- BBIO Health Care
- Exchange
- CMA Nasdaq
- BBIO Nasdaq
- Market Cap
- CMA 10.0B
- BBIO 10.4B
- IPO Year
- CMA N/A
- BBIO 2019
- Fundamental
- Price
- CMA $77.09
- BBIO $63.37
- Analyst Decision
- CMA Hold
- BBIO Strong Buy
- Analyst Count
- CMA 22
- BBIO 16
- Target Price
- CMA $71.86
- BBIO $66.50
- AVG Volume (30 Days)
- CMA 4.1M
- BBIO 2.5M
- Earning Date
- CMA 10-17-2025
- BBIO 10-29-2025
- Dividend Yield
- CMA 3.66%
- BBIO N/A
- EPS Growth
- CMA 30.51
- BBIO N/A
- EPS
- CMA 5.23
- BBIO N/A
- Revenue
- CMA $3,234,000,000.00
- BBIO $353,780,000.00
- Revenue This Year
- CMA $6.48
- BBIO $115.12
- Revenue Next Year
- CMA $3.12
- BBIO $65.29
- P/E Ratio
- CMA $14.68
- BBIO N/A
- Revenue Growth
- CMA 2.31
- BBIO 62.46
- 52 Week Low
- CMA $48.12
- BBIO $21.72
- 52 Week High
- CMA $83.22
- BBIO $69.48
- Technical
- Relative Strength Index (RSI)
- CMA 55.75
- BBIO 66.45
- Support Level
- CMA $76.18
- BBIO $52.75
- Resistance Level
- CMA $79.00
- BBIO $69.48
- Average True Range (ATR)
- CMA 2.05
- BBIO 2.78
- MACD
- CMA -0.29
- BBIO 0.97
- Stochastic Oscillator
- CMA 55.07
- BBIO 63.48
About CMA Comerica Incorporated
With assets of around $80 billion, Comerica is primarily a relationship-based commercial bank headquartered in Dallas. In addition to Texas, Comerica's other primary geographies are California and Michigan, with locations also in Arizona and Florida and select businesses operating in several other states as well as Canada and Mexico.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.